166 related articles for article (PubMed ID: 20065861)
1. Risk factors for detectable HIV-1 RNA at delivery among women receiving highly active antiretroviral therapy in the women and infants transmission study.
Katz IT; Shapiro R; Li D; Govindarajulu U; Thompson B; Watts DH; Hughes MD; Tuomala R
J Acquir Immune Defic Syndr; 2010 May; 54(1):27-34. PubMed ID: 20065861
[TBL] [Abstract][Full Text] [Related]
2. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission.
Cooper ER; Charurat M; Mofenson L; Hanson IC; Pitt J; Diaz C; Hayani K; Handelsman E; Smeriglio V; Hoff R; Blattner W;
J Acquir Immune Defic Syndr; 2002 Apr; 29(5):484-94. PubMed ID: 11981365
[TBL] [Abstract][Full Text] [Related]
3. Factors associated with lack of viral suppression at delivery among highly active antiretroviral therapy-naive women with HIV: a cohort study.
Katz IT; Leister E; Kacanek D; Hughes MD; Bardeguez A; Livingston E; Stek A; Shapiro DE; Tuomala R
Ann Intern Med; 2015 Jan; 162(2):90-9. PubMed ID: 25599347
[TBL] [Abstract][Full Text] [Related]
4. Postnatal HIV-1 transmission after cessation of infant extended antiretroviral prophylaxis and effect of maternal highly active antiretroviral therapy.
Taha TE; Kumwenda J; Cole SR; Hoover DR; Kafulafula G; Fowler MG; Thigpen MC; Li Q; Kumwenda NI; Mofenson L
J Infect Dis; 2009 Nov; 200(10):1490-7. PubMed ID: 19832114
[TBL] [Abstract][Full Text] [Related]
5. Antiretroviral regimens in pregnancy and breast-feeding in Botswana.
Shapiro RL; Hughes MD; Ogwu A; Kitch D; Lockman S; Moffat C; Makhema J; Moyo S; Thior I; McIntosh K; van Widenfelt E; Leidner J; Powis K; Asmelash A; Tumbare E; Zwerski S; Sharma U; Handelsman E; Mburu K; Jayeoba O; Moko E; Souda S; Lubega E; Akhtar M; Wester C; Tuomola R; Snowden W; Martinez-Tristani M; Mazhani L; Essex M
N Engl J Med; 2010 Jun; 362(24):2282-94. PubMed ID: 20554983
[TBL] [Abstract][Full Text] [Related]
6. Influence of short-course antenatal antiretroviral therapy on viral load and mother-to-child transmission in subsequent pregnancies among HIV-infected women.
French CE; Tookey PA; Cortina-Borja M; de Ruiter A; Townsend CL; Thorne C
Antivir Ther; 2013; 18(2):183-92. PubMed ID: 23475123
[TBL] [Abstract][Full Text] [Related]
7. Time to viral load suppression in antiretroviral-naive and -experienced HIV-infected pregnant women on highly active antiretroviral therapy: implications for pregnant women presenting late in gestation.
Aziz N; Sokoloff A; Kornak J; Leva NV; Mendiola ML; Levison J; Feakins C; Shannon M; Cohan D
BJOG; 2013 Nov; 120(12):1534-47. PubMed ID: 23924192
[TBL] [Abstract][Full Text] [Related]
8. Mother-to-child transmission of HIV infection in the era of highly active antiretroviral therapy.
European Collaborative Study
Clin Infect Dis; 2005 Feb; 40(3):458-65. PubMed ID: 15668871
[TBL] [Abstract][Full Text] [Related]
9. Antiretroviral therapy in pregnant women with advanced HIV disease and pregnancy outcomes in Abidjan, Côte d'Ivoire.
Ekouevi DK; Coffie PA; Becquet R; Tonwe-Gold B; Horo A; Thiebaut R; Leroy V; Blanche S; Dabis F; Abrams EJ
AIDS; 2008 Sep; 22(14):1815-20. PubMed ID: 18753864
[TBL] [Abstract][Full Text] [Related]
10. Effect of antiretroviral therapy on pregnancy outcome in HIV-1 positive women.
Kowalska A; Niemiec T; El Midaoui A; Burkacka E
Med Wieku Rozwoj; 2003; 7(4 Pt 1):459-68. PubMed ID: 15010556
[TBL] [Abstract][Full Text] [Related]
11. Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. Pediatric AIDS Clinical Trials Group Study 185 Team.
Mofenson LM; Lambert JS; Stiehm ER; Bethel J; Meyer WA; Whitehouse J; Moye J; Reichelderfer P; Harris DR; Fowler MG; Mathieson BJ; Nemo GJ
N Engl J Med; 1999 Aug; 341(6):385-93. PubMed ID: 10432323
[TBL] [Abstract][Full Text] [Related]
12. Highly active antiretroviral therapy versus zidovudine/nevirapine effects on early breast milk HIV type-1 Rna: a phase II randomized clinical trial.
Chung MH; Kiarie JN; Richardson BA; Lehman DA; Overbaugh J; Kinuthia J; Njiri F; John-Stewart GC
Antivir Ther; 2008; 13(6):799-807. PubMed ID: 18839781
[TBL] [Abstract][Full Text] [Related]
13. Factors associated with HIV RNA levels in pregnant women on non-suppressive highly active antiretroviral therapy at conception.
European Collaborative Study
Antivir Ther; 2010; 15(1):41-9. PubMed ID: 20167990
[TBL] [Abstract][Full Text] [Related]
14. Effects of highly active antiretroviral therapy duration and regimen on risk for mother-to-child transmission of HIV in Johannesburg, South Africa.
Hoffman RM; Black V; Technau K; van der Merwe KJ; Currier J; Coovadia A; Chersich M
J Acquir Immune Defic Syndr; 2010 May; 54(1):35-41. PubMed ID: 20216425
[TBL] [Abstract][Full Text] [Related]
15. Pregnancy outcomes among ART-naive and ART-experienced HIV-positive women: data from the ICONA foundation study group, years 1997-2013.
d'Arminio Monforte A; Galli L; Lo Caputo S; Lichtner M; Pinnetti C; Bobbio N; Francisci D; Costantini A; Cingolani A; Castelli F; Girardi E; Castagna A;
J Acquir Immune Defic Syndr; 2014 Nov; 67(3):258-67. PubMed ID: 25314248
[TBL] [Abstract][Full Text] [Related]
16. Treatment acceleration program and the experience of the DREAM program in prevention of mother-to-child transmission of HIV.
Palombi L; Marazzi MC; Voetberg A; Magid NA
AIDS; 2007 Jul; 21 Suppl 4():S65-71. PubMed ID: 17620755
[TBL] [Abstract][Full Text] [Related]
17. Maternal Highly Active Antiretroviral Therapy and Child HIV-Free Survival in Malawi, 2004-2009.
Schwartz SR; Kumwenda N; Kumwenda J; Chen S; Mofenson LM; Taylor AW; Fowler MG; Taha TE
Matern Child Health J; 2016 Mar; 20(3):542-9. PubMed ID: 26525557
[TBL] [Abstract][Full Text] [Related]
18. Antiretroviral therapy (ART) for treating HIV infection in ART-eligible pregnant women.
Sturt AS; Dokubo EK; Sint TT
Cochrane Database Syst Rev; 2010 Mar; (3):CD008440. PubMed ID: 20238370
[TBL] [Abstract][Full Text] [Related]
19. Outcomes of prevention of mother to child transmission of the human immunodeficiency virus-1 in rural Kenya--a cohort study.
Nduati EW; Hassan AS; Knight MG; Muema DM; Jahangir MN; Mwaringa SL; Etyang TJ; Rowland-Jones S; Urban BC; Berkley JA
BMC Public Health; 2015 Oct; 15():1008. PubMed ID: 26433396
[TBL] [Abstract][Full Text] [Related]
20. Use of zidovudine-sparing HAART in pregnant HIV-infected women in Europe: 2000-2009.
Tariq S; Townsend CL; Cortina-Borja M; Duong T; Elford J; Thorne C; Tookey PA; ;
J Acquir Immune Defic Syndr; 2011 Aug; 57(4):326-33. PubMed ID: 21499113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
